[go: up one dir, main page]

AR066164A1 - Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) - Google Patents

Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)

Info

Publication number
AR066164A1
AR066164A1 ARP080104050A ARP080104050A AR066164A1 AR 066164 A1 AR066164 A1 AR 066164A1 AR P080104050 A ARP080104050 A AR P080104050A AR P080104050 A ARP080104050 A AR P080104050A AR 066164 A1 AR066164 A1 AR 066164A1
Authority
AR
Argentina
Prior art keywords
group
seq
csf
iii
antigens
Prior art date
Application number
ARP080104050A
Other languages
English (en)
Inventor
Jose Carlos Escobar
Kenneth A Brasel
Dauphine Barone
Kara Olson
Jacqueline Kirchner
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR066164A1 publication Critical patent/AR066164A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se proporcionan ácidos nucleicos que codifican la proteína de union a antígenos, vectores y células que codifican los mismos. Las proteínas de union a antígenos pueden inhibir la union del GM-CSF al GM-CSFR, inhibir la proliferacion y senalizacion de líneas celulares del linaje mieloide inducidas por el GM-CSF e inhibir la activacion de monocitos humanos inducida por el GM-CSF. Reivindicacion 1: Una proteína de union a antígenos aislada que se une al GM-CSF que comprende: A) una o más regiones determinantes de la complementariedad de cadena pesada (CDRHs) que se selecciona del grupo que consiste en: (i) una CDRH1 que se selecciona del grupo que consiste en la SEQ ID NO: 10, 22, 70 94 y 142; (ii) una CDRH2 que se selecciona del grupo que consiste en la SEQ ID NO: 11, 23, 28, 35, 47, 59, 71, 95, 106, 119 y 143; (iii) una CDRH3 que se selecciona del grupo que consiste en la SEQ ID NO: 12, 24, 36, 48, 60, 72, 83, 96, 108, 120, 132 y 144; y (iv) una CDRH de (i), (ii) y (iii) que contiene una o más sustituciones, eliminaciones o inserciones de aminoácidos de no más de 4 aminoácidos; B) una o más regiones determinantes de la complementariedad de cadena liviana (CDRLs) que se selecciona del grupo que consiste en: (i) una CDRL1 que se selecciona del grupo que consiste en la SEQ ID NO: 4, 16, 30, 40, 52, 64, 88, 100, 107, 112, 118, 124, 125 y 136; (ii) una CDRL2 que se selecciona del grupo que consiste en la SEQ ID NO: 5, 17, 29, 34, 41, 65, 77, 101, 113, 130, 131 y 137; (iii) una CDRL3 que se selecciona del grupo que consiste en la SEQ ID NO: 6, 18, 42, 46, 66, 78, 84, 89, 90, 102, 114, 126 y 138; y (iv) una CDRL de (i), (ii) y (iii) que contiene una o más sustituciones, eliminaciones o inserciones de aminoácidos de no más de 4 aminoácidos; o C) una o más CDRHs de cadena pesada de A) y una o más CDRLs de cadena liviana de B).
ARP080104050A 2007-09-18 2008-09-18 Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf) AR066164A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99434307P 2007-09-18 2007-09-18
US8755108P 2008-08-08 2008-08-08

Publications (1)

Publication Number Publication Date
AR066164A1 true AR066164A1 (es) 2009-07-29

Family

ID=40210593

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104050A AR066164A1 (es) 2007-09-18 2008-09-18 Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)

Country Status (18)

Country Link
US (3) US8268311B2 (es)
EP (2) EP2236519A1 (es)
JP (1) JP2010538676A (es)
KR (1) KR101274356B1 (es)
CN (1) CN101861336A (es)
AR (1) AR066164A1 (es)
AU (1) AU2008302747B2 (es)
BR (1) BRPI0817007A2 (es)
CA (1) CA2698667C (es)
CL (1) CL2008002750A1 (es)
CR (1) CR11374A (es)
EA (1) EA201000490A1 (es)
MX (1) MX2010002968A (es)
NZ (1) NZ583787A (es)
PE (1) PE20091193A1 (es)
TW (1) TW200918553A (es)
WO (1) WO2009038760A2 (es)
ZA (1) ZA201002160B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101687926A (zh) * 2007-05-23 2010-03-31 哮喘和气道Crc有限公司 中和抗体
AU2008323608A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
RS52713B (sr) 2007-11-13 2013-08-30 Boehringer Ingelheim International Gmbh Monoklonalna antitela koja se vezuju za hgm-csf i medicinske kompozicije koje sadrže iste
WO2009134805A2 (en) 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
HUE028615T2 (en) 2008-12-22 2016-12-28 Univ Melbourne Treatment of osteoarthritis
KR101761324B1 (ko) 2008-12-22 2017-07-25 더 유니버시티 오브 멜버른 통증 치료
CA2759506A1 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
CN102439039A (zh) * 2009-05-05 2012-05-02 莫佛塞斯公司 多发性硬化的治疗
EP2640746A1 (en) * 2010-11-18 2013-09-25 Merck Serono S.A. Antibody with specificity for gm-csf (i)
US9567398B2 (en) 2010-11-18 2017-02-14 Merck Serono S.A. Antibody with specificity for GM-CSF (II)
WO2013004806A1 (en) 2011-07-06 2013-01-10 Morphosys Ag Therapeutic combinations of anti -cd20 and anti - gm - csf antibodies and uses thereof
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
EP2897977A1 (en) * 2012-09-20 2015-07-29 MorphoSys AG Treatment for rheumatoid arthritis
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
KR20220045064A (ko) 2013-08-30 2022-04-12 다케다 야쿠힌 고교 가부시키가이샤 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
KR102385802B1 (ko) 2014-05-07 2022-04-13 다케다 야쿠힝 고교 가부시키가이샤 Gm-csf 중화 화합물을 포함하는 액체 제제
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
KR102221013B1 (ko) * 2014-09-26 2021-03-02 내셔널 유니버시티 오브 싱가포르 Th-gm 세포 기능 조절 방법 및 조성물
WO2016073853A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016079277A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist in the treatment of an infectious disease
WO2016079276A1 (en) * 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease
EP3288975A1 (en) * 2015-04-29 2018-03-07 Institute for Research in Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
JP2018527903A (ja) * 2015-07-22 2018-09-27 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． Ｇｄｆ１１結合タンパク質およびその使用
PT3350220T (pt) 2015-09-15 2021-08-06 Scholar Rock Inc Anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
AU2017206069A1 (en) 2016-01-08 2018-07-19 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
PE20190205A1 (es) 2016-06-13 2019-02-07 Scholar Rock Inc Uso de inhibidores de miostatina y terapias de combinacion
IL264161B2 (en) * 2016-07-14 2025-06-01 Scholar Rock Inc Tgfb antibodies, methods, and uses
CN107840885B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
KR20190035790A (ko) * 2016-09-19 2019-04-03 아이-맵 항-gm-csf 항체 및 이것의 사용
HUE061656T2 (hu) 2017-01-06 2023-07-28 Scholar Rock Inc Metabolikus betegségek kezelése a miosztatin aktiválás gátlásával
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
AU2019374102A1 (en) * 2018-10-31 2021-06-17 Humanigen, Inc. Materials and methods for treating cancer
AU2019464494A1 (en) * 2019-09-03 2022-04-14 OncoTab, Inc. Tumor specific antibody conjugates and uses therefor
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2023520403A (ja) * 2020-04-03 2023-05-17 ソレント・セラピューティクス・インコーポレイテッド Ｌａｇ３に結合する操作された抗体
JP2020162622A (ja) * 2020-06-25 2020-10-08 インスティテュート フォー リサーチ イン バイオメディシン 多重特異性抗体によるサイトカインの非常に強力な中和およびその利用
EP4259284A1 (en) * 2020-12-10 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Canine cancer vaccine
WO2023200873A2 (en) * 2022-04-12 2023-10-19 Washington University Chimeric antigen receptor compositions and methods of using the same
IL321628A (en) 2022-12-22 2025-08-01 Scholar Rock Inc Selective and potent inhibitory antibodies for myostatin activation
CN117126277B (zh) * 2023-10-26 2024-01-23 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及其应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB8624899D0 (en) 1986-10-17 1986-11-19 Sandoz Ltd Monoclonal antibodies
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5070013A (en) 1988-05-31 1991-12-03 Schering Corporation Immunochemical assay for human granulocyte-macrophage colony stimulating factor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA905480B (en) * 1989-07-14 1991-03-27 Schering Corp Antagonists of gm-csf derived from the carboxyl terminus
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE69332981T2 (de) 1992-10-23 2004-05-19 Immunex Corp., Seattle Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
ATE509032T1 (de) * 2002-02-13 2011-05-15 Ludwig Inst For Cancer Res Ltd Chimerizierte gm-csf antikörper
US7405275B2 (en) * 2003-09-24 2008-07-29 Millennium Pharmaceuticals, Inc. Antibodies which bind human CXCR3
JP2007510622A (ja) * 2003-10-08 2007-04-26 ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ Ｂ細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物
DK1593690T3 (da) 2004-05-05 2009-11-09 Micromet Ag Fremstilling af ScFv-antistoffragmenter
KR101704809B1 (ko) * 2005-04-18 2017-02-08 암젠 리서치 (뮌헨) 게엠베하 인간 과립구 마크로파지 콜로니 자극 인자의 중화 항체
BRPI0610796B8 (pt) * 2005-05-18 2021-05-25 Morphosys Ag anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
SG170080A1 (en) * 2005-12-08 2011-04-29 Medarex Inc Human monoclonal antibodies to o8e
US7741450B2 (en) * 2006-02-08 2010-06-22 Morphotek Inc. Antibodies to GM-CSF
EA200900709A1 (ru) * 2006-11-21 2009-12-30 Калобиос Фармасьютикалс, Инк. Способы лечения хронических воспалительных заболеваний с использованием антагониста gm-csf
WO2009134805A2 (en) 2008-04-28 2009-11-05 Kalobios Pharmaceuticals, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor

Also Published As

Publication number Publication date
JP2010538676A (ja) 2010-12-16
CN101861336A (zh) 2010-10-13
WO2009038760A2 (en) 2009-03-26
EP2236519A1 (en) 2010-10-06
BRPI0817007A2 (pt) 2015-03-24
TW200918553A (en) 2009-05-01
US20130259799A1 (en) 2013-10-03
US8481704B2 (en) 2013-07-09
US20110189082A1 (en) 2011-08-04
PE20091193A1 (es) 2009-09-06
CR11374A (es) 2010-05-19
US20130071923A1 (en) 2013-03-21
ZA201002160B (en) 2011-06-29
AU2008302747B2 (en) 2012-02-02
NZ583787A (en) 2012-05-25
AU2008302747A1 (en) 2009-03-26
KR101274356B1 (ko) 2013-06-25
EP2205636A2 (en) 2010-07-14
WO2009038760A3 (en) 2009-08-20
KR20100059985A (ko) 2010-06-04
CL2008002750A1 (es) 2009-02-06
CA2698667A1 (en) 2009-03-26
US8268311B2 (en) 2012-09-18
EA201000490A1 (ru) 2010-10-29
CA2698667C (en) 2013-12-24
MX2010002968A (es) 2010-06-15

Similar Documents

Publication Publication Date Title
AR066164A1 (es) Proteinas humanas de union a antigenos del factor estimulante de colonias de megacariocitos-macrofagos(gm-csf)
CO2020014727A2 (es) Anticuerpo anti proteína reguladora de señales alfa sirpαlfa
CO6331299A2 (es) Proteinas de union a antigeno de factor de crecimiento tipo factor de crecimiento epidermico de union a heparina
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
AR078778A1 (es) Proteinas de union a antigenos de il-23
JP2020500538A5 (es)
PE20170687A1 (es) Proteinas de enlace a cd127
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
PE20230415A1 (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
PE20140133A1 (es) Nuevas proteinas de union a antigenos
AR095432A1 (es) Proteínas de unión a antígeno
NZ610153A (en) Novel anti-dr5 antibody
CO6230999A2 (es) Anticuerpo anti-esclerostina
NZ603972A (en) Anti-fgfr2 antibodies
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
PE20181327A1 (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
ES2631135T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AR082194A1 (es) Anticuerpos anti-ron
AR070821A1 (es) Anticuerpo anti- tyrp1 (antitiroxina humana)
PE20221865A1 (es) Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso

Legal Events

Date Code Title Description
FA Abandonment or withdrawal